Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TLR adaptor interacting with SLC15A4 on the lysosome (TASL) is an innate immune adaptor protein encoded by the CXorf21 gene, identified as a partner of the endolysosomal transporter SLC15A4[1][3][5]. TASL is specifically required for signaling by endolysosomal Toll-like receptors (TLR7, TLR8, TLR9), where it forms a complex with SLC15A4. This complex recruits and activates the transcription factor IRF5—a pivotal event for the production of type I interferon and pro-inflammatory cytokines in response to pathogenic nucleic acids. TASL contains a conserved pLxIS motif that mediates IRF5 recruitment, and its localization and function are strictly dependent on SLC15A4 binding. Loss of TASL disrupts IRF5 activation without affecting NF-κB or MAPK pathways, indicating a unique, non-redundant role in TLR-driven type I interferon responses. The TASL-SLC15A4 module is genetically and functionally implicated in autoimmune disorders, including systemic lupus erythematosus, making TASL a promising new target for therapeutic strategies aiming to modulate pathogenic type I interferon signaling[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TLR adaptor interacting with SLC15A4 on the lysosome (TASL).